Diaminocyclopentane – L-Lysine Adducts: Potent and selective inhibitors of human O-GlcNAcase

Patrick Weber*, Pavla Bojarová, Jitka Brouzdová, Vladimír Křen, Natalia Kulik, Arnold E. Stütz, Martin Thonhofer, Tanja M. Wrodnigg

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

A new class of compounds, namely highly substituted diaminocyclopentane-L-lysine adducts, have been discovered as potent inhibitors of O-GlcNAcase, an enzyme crucial for protein de-O-glycosylation. These inhibitors exhibit exceptional selectivity and reversibility and are the first example of human O-GlcNAcase inhibitors that are structurally related to the transition state of the rate-limiting step with the “aglycon” still in bond-length proximity. The ease of their preparation, remarkable biological activities, stability, and non-toxicity make them promising candidates for the development of anti-tau-phosphorylation agents holding significant potential for the treatment of Alzheimer's disease.

Original languageEnglish
Article number107452
JournalBioorganic Chemistry
Volume148
DOIs
Publication statusPublished - Jul 2024

Keywords

  • Alzheimer's disease
  • Diaminocyclopentane
  • Glycosidase
  • Hexosaminidase
  • Inhibition
  • O-GlcNAcase
  • Tau protein

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Drug Discovery
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Diaminocyclopentane – L-Lysine Adducts: Potent and selective inhibitors of human O-GlcNAcase'. Together they form a unique fingerprint.

Cite this